AXGN vs TBPH: fair value comparison
Axogen, Inc. and Theravance Biopharma, Inc. · Updated 2026-10-19
AXGN is still awaiting a full valuation verdict under our six-validated-windows standard. TBPH is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, TBPH currently ranks higher by quality score.
| AXGN | TBPH | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $34.62 | $17.03 |
| 12-month range | $17.77–$51.73 | $13.57–$20.74 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #34 of 301 Healthcare | #33 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | — | Undervalued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: AXGN fair value analysis · TBPH fair value analysis